Kylee Maclachlan

1.7k total citations
43 papers, 343 citations indexed

About

Kylee Maclachlan is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Kylee Maclachlan has authored 43 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 23 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Kylee Maclachlan's work include Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (5 papers). Kylee Maclachlan is often cited by papers focused on Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (5 papers). Kylee Maclachlan collaborates with scholars based in United States, Australia and Germany. Kylee Maclachlan's co-authors include Ola Landgren, Benjamin Diamond, Simon J. Harrison, Ross D. Hannan, Gretchen Poortinga, Elaine Sanij, Natalie Brajanovski, Richard B. Pearson, Francesco Maura and Amit Khot and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kylee Maclachlan

36 papers receiving 340 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kylee Maclachlan United States 9 268 168 118 38 20 43 343
Even H. Rustad United States 9 159 0.6× 214 1.3× 147 1.2× 52 1.4× 46 2.3× 13 306
Cinnie Yentia Soekojo Singapore 10 202 0.8× 176 1.0× 110 0.9× 13 0.3× 21 1.1× 30 298
Lüder Hinrich Meyer Germany 10 181 0.7× 144 0.9× 116 1.0× 44 1.2× 36 1.8× 24 381
Kaiyang Ding China 9 100 0.4× 107 0.6× 113 1.0× 28 0.7× 36 1.8× 51 241
Andrea Zangrando Italy 8 147 0.5× 123 0.7× 95 0.8× 46 1.2× 23 1.1× 9 303
Stephan Bohl Germany 8 176 0.7× 159 0.9× 56 0.5× 28 0.7× 8 0.4× 16 329
Christine Greil Germany 9 176 0.7× 181 1.1× 130 1.1× 28 0.7× 17 0.8× 24 295
Brandon Blue United States 6 72 0.3× 79 0.5× 68 0.6× 46 1.2× 12 0.6× 27 163
Evžen Gregora Czechia 11 218 0.8× 253 1.5× 130 1.1× 28 0.7× 22 1.1× 29 301
Heather Leu United States 4 238 0.9× 68 0.4× 37 0.3× 68 1.8× 8 0.4× 14 283

Countries citing papers authored by Kylee Maclachlan

Since Specialization
Citations

This map shows the geographic impact of Kylee Maclachlan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kylee Maclachlan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kylee Maclachlan more than expected).

Fields of papers citing papers by Kylee Maclachlan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kylee Maclachlan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kylee Maclachlan. The network helps show where Kylee Maclachlan may publish in the future.

Co-authorship network of co-authors of Kylee Maclachlan

This figure shows the co-authorship network connecting the top 25 collaborators of Kylee Maclachlan. A scholar is included among the top collaborators of Kylee Maclachlan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kylee Maclachlan. Kylee Maclachlan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Firestone, Ross, Jung Hun Oh, Viswatej Avutu, et al.. (2025). High WEE1 expression is independently linked to poor survival in multiple myeloma. Blood Cancer Journal. 15(1). 22–22.
2.
Kazandjian, Dickran, Benjamin Diamond, Romanos Sklavenitis‐Pistofidis, et al.. (2024). Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Clinical Cancer Research. 30(19). 4482–4490. 5 indexed citations
3.
Tauro, Marilena, Bachisio Ziccheddu, Alexandra M. Poos, et al.. (2024). Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma. Blood. 144(Supplement 1). 3276–3276.
4.
Maclachlan, Kylee, Jian Kang, Andrew Cuddihy, et al.. (2024). Targeting the ribosome to treat multiple myeloma. SHILAP Revista de lepidopterología. 32(1). 200771–200771. 6 indexed citations
5.
Tan, Carlyn, Andriy Derkach, Kylee Maclachlan, et al.. (2024). Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 42(16_suppl). 7536–7536. 8 indexed citations
6.
Chojnacka, Monika, Benjamin Diamond, Bachisio Ziccheddu, et al.. (2023). Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research. 30(3). 575–585. 1 indexed citations
7.
Derkach, Andriy, Billel Gasmi, Theodora Anagnostou, et al.. (2023). T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis. Blood. 142(Supplement 1). 3326–3326. 1 indexed citations
8.
Tauro, Marilena, Bachisio Ziccheddu, Alexandra M. Poos, et al.. (2023). Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma. Blood. 142(Supplement 1). 639–639. 1 indexed citations
9.
Diamond, Benjamin, Dickran Kazandjian, Bachisio Ziccheddu, et al.. (2023). Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma. Blood. 142(Supplement 1). 757–757. 1 indexed citations
10.
Firestone, Ross, Andriy Derkach, Kylee Maclachlan, et al.. (2023). P-486 Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S307–S308. 1 indexed citations
11.
Maclachlan, Kylee, Rena Elkin, Larry Norton, et al.. (2023). Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival. Blood Cancer Journal. 13(1). 175–175. 2 indexed citations
12.
Camp, Nicola J., Celine M. Vachon, Michelle A.T. Hildebrandt, et al.. (2023). Abstract 5229: Pathogenic germline mutations and risk of multiple myeloma. Cancer Research. 83(7_Supplement). 5229–5229.
13.
Maclachlan, Kylee, Tina Bagratuni, Efstathios Kastritis, et al.. (2022). Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations. Blood Advances. 7(6). 971–981. 1 indexed citations
14.
Maura, Francesco, Eileen M. Boyle, Even H Rustad, et al.. (2021). Chromothripsis as a pathogenic driver of multiple myeloma. Seminars in Cell and Developmental Biology. 123. 115–123. 25 indexed citations
15.
Maclachlan, Kylee, Neil Came, Benjamin Diamond, et al.. (2021). Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. Pathology. 53(3). 385–399. 16 indexed citations
16.
Maclachlan, Kylee, Even H Rustad, Andriy Derkach, et al.. (2021). Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nature Communications. 12(1). 5172–5172. 26 indexed citations
17.
Diamond, Benjamin, Even H Rustad, Kylee Maclachlan, et al.. (2020). Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Reviews. 46. 100732–100732. 17 indexed citations
18.
Khot, Amit, Natalie Brajanovski, Donald P. Cameron, et al.. (2019). First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discovery. 9(8). 1036–1049. 132 indexed citations
19.
Stevens, Hannah, Huyen Tran, Sanjeev Chunilal, & Kylee Maclachlan. (2019). Weight-Based Enoxaparin for Venous Thromboembolism in Obesity Gives Similar Anti-Xa Levels to Patients <100 kg, with No Increase in Major Bleeding. Seminars in Thrombosis and Hemostasis. 45(1). 94–99. 11 indexed citations
20.
Maclachlan, Kylee, Andrew Cuddihy, Nadine Hein, et al.. (2017). Novel Combination Therapies with the RNA Polymerase I Inhibitor CX-5461 Significantly Improve Efficacy in Multiple Myeloma. Blood. 130. 1805. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Even H. Rustad Breakdown of academic impact, for papers by Cinnie Yentia Soekojo Breakdown of academic impact, for papers by Lüder Hinrich Meyer Breakdown of academic impact, for papers by Kaiyang Ding Breakdown of academic impact, for papers by Andrea Zangrando Breakdown of academic impact, for papers by Stephan Bohl Breakdown of academic impact, for papers by Christine Greil Breakdown of academic impact, for papers by Brandon Blue Breakdown of academic impact, for papers by Evžen Gregora Breakdown of academic impact, for papers by Heather Leu
Rankless by CCL
2026